Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Director | June 11, 2026 | June 15, 2026 |
| INSMED IncINSM · Entity 3174 | Chief Operating Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 3,555 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 3,555 · Balance 3,555 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10 | Direct | 14,620 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 14,620 · Balance 14,620 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
INSMED Inc
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,024 |
Reported balance
After 2026-08-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-10 · Exercise / conversion · Acquired 82,280 · Balance 181,024 F1: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 257,624 |
Reported balance
After 2026-08-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-10 · Exercise / conversion · Acquired 76,600 · Balance 257,624 |
| Common StockSEC Table I · non-derivative | Direct | 338,594 |
Reported balance
After 2026-08-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Acquired 80,970 · Balance 338,594 |
| Common StockSEC Table I · non-derivative | Direct | 98,744 |
Reported balance
After 2026-08-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-08-10 · Sale · Disposed 239,850 · Balance 98,744 F2: This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2027-01-05 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-10 · Exercise / conversion · Disposed 82,280 · Balance 0 F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-10 · Exercise / conversion · Disposed 76,600 · Balance 0 F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Exercise / conversion · Disposed 80,970 · Balance 0 F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
F2: This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Landos Biopharma, Inc.
Report date May 23, 2024 · Filed May 23, 2024
Section 16 reporting ended · disclosed 2024-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Disposition to issuer · Disposed 1,800 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 | Direct | 0 |
Reported balance
After 2024-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-23 · Disposition to issuer · Disposed 1,800 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 | Direct | 0 |
Reported balance
After 2024-05-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-23 · Disposition to issuer · Disposed 3,600 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 15, 2024 20:31 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 71,160 | $0.00 Strike: $25.83 | $0.00 |
DisclosureSEC source: 0001628280-24-023589 · wk-form4_1715805079.xml · derivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,160 Underlying: Common Stock · 71,160 shares Expires 2034-05-13 F5 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter through the fourth anniversary of the Initial Vesting Date. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:31 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023589 · wk-form4_1715805079.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,077 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% percent on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| January 12, 2024 Filed Jan 12, 2024 21:05 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,251 | $28.63 | $150,336.13 |
DisclosureSEC source: 0001628280-24-001252 · wk-form4_1705093523.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,559 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:06 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,536 | $28.90 | $102,190.40 |
DisclosureSEC source: 0001628280-24-001158 · wk-form4_1705007154.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,810 F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:06 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,837 | $29.25 | $112,232.25 |
DisclosureSEC source: 0001628280-24-001158 · wk-form4_1705007154.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,346 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 3,837 shares sold at prices ranging from $29.19 to $29.28 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 22:26 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,042 | $29.21 | $88,864.43 |
DisclosureSEC source: 0001628280-24-000690 · wk-form4_1704493596.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,183 F3 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:26 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 63,560 | $0.00 Strike: $29.13 | $0.00 |
DisclosureSEC source: 0001628280-24-000690 · wk-form4_1704493596.xml · derivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,560 Underlying: Common Stock · 63,560 shares Expires 2034-01-04 F4 · derivative.exercise_date: Stock options granted under the Company's Amended and Restated 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:26 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 12,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-000690 · wk-form4_1704493596.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,225 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 4, 2024, for no consideration. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:05 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 8,981 | $19.32 | $173,512.92 |
DisclosureSEC source: 0001628280-23-022218 · wf-form4_168685949558953.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,352 F1 · kind: The reported sale occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2023. F2 · price: This is the weighted average sales price representing 8,981 shares sold at prices ranging from $19.23 to $19.46 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 23, 2023 Filed May 24, 2023 21:49 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-23-031939 · doc4.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2033-05-22 F1 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on May 23, 2024, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 17, 2023 Filed May 17, 2023 20:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,448 | $18.12 | $44,357.76 |
DisclosureSEC source: 0001628280-23-018673 · wf-form4_168435404211099.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,333 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,521 | $18.39 | $27,971.19 |
DisclosureSEC source: 0001628280-23-018673 · wf-form4_168435404211099.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,781 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,847 | $19.27 | $54,861.69 |
DisclosureSEC source: 0001628280-23-018673 · wf-form4_168435404211099.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,302 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 2,847 shares sold at prices ranging from $19.26 to $19.28 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:06 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock · Derivative | 146,220 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0001628280-23-018152 · wf-form4_168418117556876.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,220 Underlying: Common Stock · 146,220 shares Expires 2033-05-11 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:06 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 31,662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018152 · wf-form4_168418117556876.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,149 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2023, for no consideration. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:06 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,194 | $17.99 | $57,460.06 |
DisclosureSEC source: 0001628280-23-000957 · wf-form4_167355760242570.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,487 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 3,194 shares sold at prices ranging from $17.98 to $18.01 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:08 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 34,860 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0001685904-23-000001 · wf-form4_167303931068897.xml · derivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,860 Underlying: Common Stock · 34,860 shares Expires 2033-01-05 F4 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of the grant. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:08 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 7,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001685904-23-000001 · wf-form4_167303931068897.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,681 F2 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F3 · price: Each Restricted Stock Unit was received as a grant on January 5, 2023, for no consideration. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:08 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,044 | $19.75 | $60,119.00 |
DisclosureSEC source: 0001685904-23-000001 · wf-form4_167303931068897.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,083 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 22:03 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 11,855 | $18.80 | $222,874.00 |
DisclosureSEC source: 0001685904-22-000001 · wf-form4_166915458164192.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,127 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: This is the weighted average sales price representing the shares sold at prices ranging from $18.78 to $18.86 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 12:52 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-22-035283 · doc4.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on June 7, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,022 | $20.34 | $41,127.48 |
DisclosureSEC source: 0001140361-22-019782 · form4.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,982 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: This is the weighted average sales price representing the shares sold at prices ranging from $20.21 to $20.45 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,394 | $18.45 | $25,719.30 |
DisclosureSEC source: 0001140361-22-019782 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,004 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:12 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 129,490 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001140361-22-019173 · form4.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,490 Underlying: Common Stock · 129,490 shares Expires 2032-05-11 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:12 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 27,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019173 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,398 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2022, for no consideration. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 21:19 UTC | Landos Biopharma, Inc. LABP · Entity 90644 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001209191-22-017865 · doc4.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2032-03-07 F1 · derivative.exercise_date: The shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments beginning on March 8, 2022, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 21:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,217 | $24.58 | $29,913.86 |
DisclosureSEC source: 0001140361-22-001604 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,938 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,759 | $26.00 | $45,734.00 |
DisclosureSEC source: 0001140361-22-000963 · form4.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,420 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:09 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 85,690 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001140361-22-001167 · form4.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,690 Underlying: Common Stock · 85,690 shares Expires 2032-01-06 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:09 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 17,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-001167 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,155 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 6, 2022, for no consideration. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,068 | $27.61 | $84,707.48 |
DisclosureSEC source: 0001140361-22-000963 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,179 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| May 15, 2021 Filed May 18, 2021 20:43 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 2,477 | $26.23 | $64,971.71 |
DisclosureSEC source: 0001140361-21-017898 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,247 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:10 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 68,640 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001140361-21-017469 · form4.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,640 Underlying: Common Stock · 68,640 shares Expires 2031-05-12 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:10 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017469 · form4.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,724 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 12, 2021, for no consideration. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:40 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 54,720 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001104659-21-002512 · tm211774-12_4seq1.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,720 Underlying: Common Stock · 54,720 shares Expires 2031-01-07 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:40 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 11,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-002512 · tm211774-12_4seq1.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,552 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 7, 2021, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:13 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 1,223 | $33.42 | $40,872.66 |
DisclosureSEC source: 0001104659-21-001605 · tm211774d4_4seq1.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,533 F2 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| January 03, 2021 Filed Jan 6, 2021 22:13 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 2,275 | $33.29 | $75,734.75 |
DisclosureSEC source: 0001104659-21-001605 · tm211774d4_4seq1.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,756 F2 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| May 15, 2020 Filed Jan 6, 2021 22:13 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 1,690 | $25.46 | $43,027.40 |
DisclosureSEC source: 0001104659-21-001605 · tm211774d4_4seq1.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,031 F1 · shares: Represents the withholding of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. This transaction was not reported previously due to a clerical error. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:05 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 141,300 | $0.00 Strike: $23.75 | $0.00 |
DisclosureSEC source: 0001127430-20-000021 · edgar.xml · derivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,300 Underlying: Common Stock · 141,300 shares Expires 2030-01-03 F4 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:05 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 1,414 | $23.75 | $33,582.50 |
DisclosureSEC source: 0001127430-20-000021 · edgar.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,721 F3 · price: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:05 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 26,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-20-000021 · edgar.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,135 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 3, 2020, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:12 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 24,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-19-000133 · edgar.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,820 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: 100% on the third anniversary of the date of grant. F2 · price: Each Restricted Stock Unit was granted on November 18, 2019, for no consideration, and represents a contingent right to receive one share of Common Stock. F3 · balance_after: Includes 1,789 shares acquired through the Company's 2018 Employee Stock Purchase Plan for the six-month period ended July 31, 2019. Read SEC document |
| May 15, 2019 Filed May 16, 2019 21:12 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 21,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-19-000068 · edgar.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,168 F1 · shares: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 15, 2019, for no consideration, and represents a contingent right to receive one share of Common Stock. F3 · balance_after: Includes 1,015 shares acquired through the Company's 2018 Employee Stock Purchase Plan for the six-month period ended December 31, 2018. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:07 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 231,310 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001127430-19-000017 · edgar.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,310 Underlying: Common Stock · 231,310 shares Expires 2029-01-03 F1 · derivative.exercise_date: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:07 UTC | INSMED Inc INSM · Entity 3174 | PurchaseCommon Stock | 3,000 | $15.97 | $47,907.00 |
DisclosureSEC source: 0001127430-18-000067 · edgar.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,594 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.95 to $15.98. The prices reported above reflect the weighted average price. The number of shares sold at each separate price will be made available to the SEC staff, the issuer or a security holder of the issuer upon request. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 21:09 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 80,970 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001127430-18-000016 · edgar.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,970 Underlying: Common Stock · 80,970 shares Expires 2028-01-04 F3 · derivative.exercise_date: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 21:09 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 15,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-18-000016 · edgar.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,594 F1 · shares: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 4, 2018, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:32 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 76,600 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001127430-17-000047 · edgar.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,600 Underlying: Common Stock · 76,600 shares Expires 2027-05-17 F1 · derivative.exercise_date: Stock options granted under the Company's 2015 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 21:17 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 82,280 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001127430-17-000009 · edgar.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,280 Underlying: Common Stock · 82,280 shares Expires 2027-01-05 F1 · derivative.exercise_date: Stock options granted under the Company's 2015 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.